Medicines losing patent protection

MonthYear

April 2026

5 medicines lost their last listed patent or exclusivity in April 2026.

Apr 2Treximetnaproxen sodium and sumatriptan succinate · Azurity Pharmaceuticals Inc
Apr 28Vimpat · Tablet (oral)lacosamide · UCB Inc
Apr 28Vimpat · Solution (intravenous)lacosamide · UCB Inc
Apr 28Vimpat · Solution (oral)lacosamide · UCB Inc
Apr 30Zetiaezetimibe · Organon LLC a sub of Organon and Co

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits